Skip to main content

Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the fourth quarter ended April 30, 2022, on Thursday, July 21, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 908668. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 46134, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/708456/Champions-Oncology-to-Announce-Fourth-Quarter-Financial-Results-on-Thursday-July-21-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.76
+5.49 (2.48%)
AAPL  272.19
+0.35 (0.13%)
AMD  201.06
+2.95 (1.49%)
BAC  54.26
-0.29 (-0.53%)
GOOG  303.75
+5.69 (1.91%)
META  664.45
+14.95 (2.30%)
MSFT  483.98
+7.86 (1.65%)
NVDA  174.14
+3.20 (1.87%)
ORCL  180.03
+1.57 (0.88%)
TSLA  483.37
+16.11 (3.45%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.